SCHEMBL240395

SCHEMBL240395

Cc1cc2ncc3cc(-c4ccccc4C(F)(F)F)c(Cl)nc3n2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.41
TRPA1 O75762 7/20 0.40
TRPM8 Q7Z2W7 3/20 0.40
TRPV1 Q8NER1 2/20 0.40
TP53 P04637 3/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
NTSR1 P30989 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3R2 O00459 1/20 0.35
PIK3CG P48736 1/20 0.35
CRHR1 P34998 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239018 0.85 NPC1 (0.40) TP53KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL238671 0.85 NPC1 (0.41) HSD11B1TP53KMT2ASMN1; SMN2MEN1
SCHEMBL238754 0.85 NPC1 (0.41) TP53KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL235500 0.83 KMT2A (0.40) TP53KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL235881 0.81 RAB9A (0.48) TP53KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL239054 0.81 TSHR (0.45) TP53KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL238236 0.80 GABRA1 (0.42) TP53KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL237892 0.77 RAB9A (0.49) TP53KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL238176 0.77 MAOB (0.40) TP53KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL236118 0.76 NPC1 (0.41) TP53KMT2ASMN1; SMN2MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 HSD11B1 2964/4885TRPA1 4818/4885TRPM8 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.